Reviews/Chronic Pain Pharmacotherapy/Cannabis cognitive adverse effects
Can · CPP-CAN-03 · v2
Carefully controlled experiments show that THC, the active ingredient in cannabis, acutely impairs memory and attention compared with a dummy treatment, and this effect holds up across several independent laboratories [22][23][24][25]. Only one of these trials actually tested a prescribed-style medicinal cannabis product at a standard therapeutic dose, and it found mild, specific dips in visuospatial working memory and pattern recognition in healthy adults while leaving mood largely intact [20]. Larger observational studies of heavy recreational users link long-term use to memory and attention problems, but these cannot speak directly to supervised therapeutic dosing [30][32][19]. The panel judged the direction of the effect well supported and genuinely causal, but noted that most of the strong evidence comes from recreational THC challenge studies rather than patients taking cannabis as medicine. That gap between the evidence base and the exact claim, together with the mildness of the one on-target study, is why the panel stopped short of its top tier.
Placebo-controlled randomised trials demonstrate that THC causes acute cognitive impairment: impaired verbal episodic memory at 8 mg vaporised [22], dose-dependent impairment of reaction time, accuracy and time perception at 7.5 and 15 mg oral [23], and impaired neuropsychological performance at 2.5 mg intravenous [25], with a further THC-challenge RCT confirming cognitive effects in healthy men [24]. The single trial of an actual medicinal product (100 mg CBD and 5 mg THC) at a standard sublingual dose impaired select aspects of visuospatial working memory and delayed pattern recognition in healthy adults [20]. Observational cohort and cross-sectional data link heavier recreational use to deficits in memory, attention and working memory [30][32] and to altered neurodevelopment in adolescence [19]. Together these establish an acute, causal, THC-driven cognitive signal, strongest in recreational paradigms. The contested point: The division is scope, not direction: only [20] tests a medicinal cannabis product at a therapeutic dose, and its effects were mild and select, whereas the strongest causal evidence [22][23][24][25] comes from recreational THC challenges at overlapping but not identical doses. The autism therapeutic RCT [14] reported only somnolence and appetite change rather than cognitive adverse events, offering an on-scope counter-signal.
All 39 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Pain Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Only [20] tests an actual medicinal cannabis product at a therapeutic dose; the core causal RCTs [22][23][24][25] use recreational THC challenge paradigms, so applying them to 'medical cannabis' is a population/intent substitution.
Dose indirectness: [25] is 2.5 mg IV, [23] up to 15 mg oral, [22] 8 mg vaporised — experimental doses overlapping but not equal to prescribed therapeutic regimens, many of which are CBD-dominant.
Where it remains uncertain. Nearly all strong causal evidence uses recreational THC challenge paradigms in healthy volunteers [22][23][24][25], and the one on-scope therapeutic trial found only mild, select effects [20], while a therapeutic RCT in autism flagged no cognitive adverse events [14].
Aleatory
Response to a therapeutic dose varies by person; [20] noted drowsiness or sedation in 23 % of participants and plasma concentrations did not correlate with cognitive alterations, and [21] shows tolerance differs between occasional and chronic users.
Epistemic
The corpus lacks trials in patients taking prescribed cannabis therapeutically; causal evidence is drawn from healthy volunteers and recreational users [22][24][25].
The load-bearing papers from a corpus of 39, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Direct: a medicinal cannabis oil (100 mg CBD, 5 mg THC) at a standard therapeutic sublingual dose causally impaired specific cognitive measures in a double-blind RCT
“An acute dose of CannEpil impairs select aspects of visuospatial working memory and delayed pattern recognition, while largely preserving mood states among healthy individuals.”
Panel auditInternal validity: medium · scope of inference: Acute neurocognitive effect of a single therapeutic dose of a CBD-dominant medical cannabis oil in healthy adults.Key limitations: small sample · single acute dose · healthy not patient population · select cognitive domains only
Causal RCT evidence that vaporised THC (8 mg) impairs verbal memory versus placebo; CBD did not mitigate
“impaired verbal episodic memory (MD = -2.7, 95% CI = -4.1 to -1.4; MD = -2.9, 95% CI = -4.1 to -1.7)”
Panel auditInternal validity: medium · scope of inference: Acute cognitive effects of vaporized cannabis in adolescent and adult recreational users.Key limitations: recreational dose not therapeutic · users only · acute single session
Causal, dose-dependent cognitive impairment from oral THC (7.5-15 mg) under double-blind conditions
“adolescents were more sensitive to performance impairing effects, exhibiting dose-dependent impairments on reaction time, response accuracy, and time perception”
Panel auditInternal validity: medium · scope of inference: Acute cognitive effects of oral THC in near-naive adolescents and adults.Key limitations: small sample · experimental not therapeutic · near-naive users
Adverse events reported were somnolence and decreased appetite, not cognitive impairment, which was not assessed.
Panel auditInternal validity: high · scope of inference: Behavioural efficacy and tolerability of cannabinoids in children and young people with autism.Key limitations: no cognitive outcome · somnolence not cognition · wide age range
4 of 39 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Converging placebo-controlled RCT evidence establishes causal acute cognitive impairment from THC, but population and dose indirectness and the mildness of the one truly therapeutic-dose study keep confidence short of Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Cognition in prescribed-cannabis patients. The claim concerns patients at therapeutic doses, yet causal evidence comes from healthy volunteers and recreational users [22][24][25]; patients may differ through tolerance [21] and indication effects. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Placebo-controlled RCT measuring neurocognition in a patient population receiving a licensed medicinal cannabis product at prescribed doses over a sustained period.
Open question: Does medicinal cannabis at prescribed therapeutic doses cause cognitive adverse effects in the patient populations who actually receive it? Why it is still open: Only [20] tests a medicinal product and only in healthy volunteers; the causal RCTs [22][23][24][25] use recreational THC challenges.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19